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Eur J Vasc Endovasc Surg (2020) 60, 1e2EDITORIALComparison of Laser Ablation, Foam Sclerotherapy and Surgery (CLASS) TrialThe five year outcomes of the CLASS trial, which compared
three treatments for patients with symptomatic primary
varicose veins, were published recently.1 In that study, 798
participants were randomised to endovenous laser ablation
of the main incompetent venous trunk, with foam sclero-
therapy for residual non-trunk varicosities, ultrasound
guided foam sclerotherapy alone, or surgery. Study
recruitment occurred between November 2008 and
October 2012. At that time all the three treatments had
been shown to have good technical and short term clinician
reported outcomes. However, there was little evidence
about patient reported outcomes, medium term clinical
outcomes (up to five years), and cost effectiveness of the
endovenous treatments.2e4
The primary outcome measures were quality of life at six
months and five years; and cost effectiveness (cost per
quality adjusted life year [QALY] gained). Secondary out-
comes were complication rates and measures of clinical
success, such as presence of varicose veins, return to ac-
tivities, and Venous Clinical Severity Score; and technical
success (truncal ablation). Return to normal activities was
assessed, using a specially developed questionnaire.5
Six month results of the trial were published in 2014:5e7
all three treatments were shown to be safe and effective,
but laser ablation and foam sclerotherapy were associated
with a quicker return to normal activities than surgery. After
five years there was still a substantial response rate, with
75% of patients reporting their outcomes. For the five year
analysis, to account for multiple testing, only primary out-
comes with a p < .003 were considered to be significant.
QoL was improved in all groups compared with baseline.
QoL measures after laser ablation and surgical treatment
were superior to those after foam sclerotherapy: this sig-
nificant clinical difference was much more marked at five
year follow up than at six month follow up. There were no
differences in disease specific QoL between the laser abla-
tion and surgery groups; or in generic quality of life be-
tween the three groups.
The proportion of patients who reported having no
varicose veins after five years was lower than predicted in
previously published cost effective analysis models: foam
sclerotherapy 47%, surgery 54%, and laser 58%.8 The extent
of varicose veins at five years, by participant reported visual
analogue score was less for laser ablation (p < .001) and for
surgery (p < .001) than for foam sclerotherapy. Neverthe-
less, patient satisfaction was high across all three groups,1078-5884/Crown Copyright  2020 Published by Elsevier B.V. on behalf of
European Society for Vascular Surgery. All rights reserved.
https://doi.org/10.1016/j.ejvs.2020.03.040and the majority of participants would recommend the
treatment they had received to family or friends. The re-
intervention rate over the five year period was low (sur-
gery 7%, laser 11%, and foam sclerotherapy 14%).
With regard to cost effectiveness, our previously con-
structed Markov model was updated to take account of all
the five year findings. This has not altered our previous
conclusion, despite a lower rate of re-intervention and a
higher recurrence rate than previously predicted, laser
ablation under local anaesthetic in a treatment room
setting had the highest probability (77%) of being cost
effective (using a ceiling willingness to pay ratio of £20 000
per QALY gained). The trial based analysis showed a similar
outcome for the three way comparison. There was consid-
erable uncertainty in the two way analysis comparing foam
sclerotherapy and surgery, with differences in the model
and trial based analysis.
Our findings provide clinical, quality of life, and cost in-
formation to guide choices of patients and venous spe-
cialists between the several treatment options available for
varicose veins. The trial did not include radiofrequency
ablation (RFA), which is a commonly used endothermal
alternative to laser ablation. By and large, the evidence
shows little difference in outcomes between laser ablation
and RFA, so RFA probably has similar advantages, provided
that it can be done at similar cost to laser.8 When using
endothermal ablation (laser or RFA), practice varies sub-
stantially in terms of whether and when varicosities are
treated, concomitantly or at a later date, and by foam or
phlebectomies. These variations will affect both costs and
outcomes, and they need to be considered alongside the
findings of the CLASS trial in which later treatment with
foam sclerotherapy was performed in 31% of participants in
the laser ablation group.
Foam sclerotherapy is technically possible in most pa-
tients, and a case has been made previously that it is so
inexpensive that it dominates other treatments in terms of
cost.9 However, the poorer long term clinical outcomes and
cost effectiveness documented in the CLASS trial should
prompt caution in promoting foam sclerotherapy as a
routine treatment for patients with primary varicose veins.
Guidance from NICE (the National Institute for Health and
Care Excellence) in the UK, published in 2013, recommends
foam as second choice after endothermal ablation, for
treating varicose veins. When the guidance is reviewed, this
recommendation may need to be reconsidered in the light
of the CLASS results.8
Finally, CLASS has shown how commonly varicose veins
recur, five years after apparently thorough treatment. This
2 Editorialhighlights the chronic tendency that many people have for
developing more veins and could call into question the
value of treatment, especially in publicly funded health
services. In the UK, NICE recommendations that patients
with troublesome symptomatic varicose veins (CEAP classes
C2eC3) should be eligible for treatment have been widely
ignored by health service commissioners and providers,
who restrict treatment to those with ulcer, bleeding, or
phlebitis. Balancing cost and value is a challenge for
healthcare systems worldwide. The CLASS trial provides
important new evidence that should help to influence the
decisions of policy makers, payers, clinicians, and patients
with varicose veins.
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